FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
-
-
-
-
-
-
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Prepar
-
-
-
-
-
-
-
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
-
-
-
-
-
-
-
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
-
-
-
-
-
-
-
Emergent BioSolutions (EBS) Gains Exclusive Commercial Rights to KLOXXADO Nasal Spray from Hikma Pharmaceuticals
-
328,433 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

